Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Brand Equity Group Sweden AB in connection with its acquisition of PREVOX REKLAM Aktiebolag and Jonas Anderzson of Sweden AB
Mandate

Vinge has advised Brand Equity Group Sweden AB in connection with its acquisition of PREVOX REKLAM Aktiebolag and Jonas Anderzson of Sweden AB

June 09, 2025 Data protection and processing of personal data Commercial Agreements M&A

Vinge has advised Brand Equity Group Sweden AB in connection with its parallel acquisitions of PREVOX REKLAM Aktiebolag and Jonas Anderzson of Sweden AB. The acquired businesses are engaged in product media activities, with a primary focus on marketing and production of product media. Through these acquisitions, Brand Equity Group Sweden AB strengthens its position in Sweden within product media and brand communication.

Vinges team consisted mainly of Jonas Johansson, Philip Moré och Linn Aho (M&A), Christoffer Nordin (Commercial Agreements), Nicklas Thorgerzon (GDPR) and Jasmina Skandrani (Transaction Support Coordinator).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025